Activation of CXCR7 Limits Atherosclerosis and Improves Hyperlipidemia by Increasing Cholesterol Uptake in Adipose Tissue
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background—: The aim of this study was to determine the role of the chemokine receptor CXCR7 in atherosclerosis and vascular remodeling. CXCR7 is the alternative receptor of CXCL12, which regulates stem cell–mediated vascular repair and limits atherosclerosis via its receptor, CXCR4. Methods and Results—: Wire-induced injury of the carotid artery was performed in mice with a ubiquitous, conditional deletion of CXCR7 and in mice treated with the synthetic CXCR7 ligand CCX771. The effect of CCX771 treatment on atherosclerosis was studied in apolipoprotein E–deficient ( Apoe −/− ) mice fed a high-fat diet for 12 weeks. Lipoprotein fractions were quantified in the plasma of Apoe −/− mice by fast protein liquid chromatography. Uptake of DiI-labeled very low-density lipoprotein to adipose tissue was determined by 2-photon microscopy. We show that genetic deficiency of Cxcr7 increased neointima formation and lesional macrophage accumulation in hyperlipidemic mice after vascular injury. This was related to increased serum cholesterol levels and subsequent hyperlipidemia-induced monocytosis. Conversely, administration of the CXCR7 ligand CCX771 to Apoe −/− mice inhibited lesion formation and ameliorated hyperlipidemia after vascular injury and during atherosclerosis. Treatment with CCX771 reduced circulating very low-density lipoprotein levels but not low-density lipoprotein or high-density lipoprotein levels and increased uptake of very low-density lipoprotein into Cxcr7 -expressing white adipose tissue. This effect of CCX771 was associated with an enhanced lipase activity and reduced expression of Angptl4 in adipose tissue. Conclusions—: CXCR7 regulates blood cholesterol by promoting its uptake in adipose tissue. This unexpected cholesterol-lowering effect of CXCR7 is beneficial for atherosclerotic vascular diseases, presumably via amelioration of hyperlipidemia-induced monocytosis, and can be augmented with a synthetic CXCR7 ligand.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E
Zhang, S. H., Reddick, R. L., Piedrahita, J. A., & Maeda, N. (1992) · Science · doi:10.1126/science.1411543 · Cited by 2,237 · cited 1×
“The type of dyslipidemia observed in Apoe mice is characterized by an elevation of VLDL/intermediate-density lipoprotein–derived cholesterol levels, whereas LDL cholesterol levels are only mildly increased and HDL cholesterol levels are reduced.(31) Treatment with CCX771 lowered only circulating VLDL levels in Apoe mi…”
BackgroundTsou, C.-L., Peters, W., Si, Y., Slaymaker, S., Aslanian, A. M., Weisberg, S. P., Mack, M., & Charo, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29919 · Cited by 1,152
Murphy, A. J., Akhtari, M., Tolani, S., Pagler, T., Bijl, N., Kuo, C.-L., Wang, M., Sanson, M., Abramowicz, S., Welch, C., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57559 · Cited by 521
Mandard, S., Zandbergen, F., van Straten, E., Wahli, W., Kuipers, F., Müller, M., & Kersten, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m506519200 · Cited by 433
Köster, A., Chao, Y. B., Mosior, M., Ford, A., Gonzalez-DeWhitt, P. A., Hale, J. E., Li, D., Qiu, Y., Fraser, C. C., Yang, D. D., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0476 · Cited by 427 · cited 1×
“results in hypertriglyceridemia and hypercholesterolemia in mice.(41,42) Moreover, chronic intermittent hypoxia increases VLDL levels, reduces adipose Lpl activity, and promotes ath-”
BackgroundChronic intermittent hypoxia induces atherosclerosis via activation of adipose angiopoietin-like 4
Drager, L. F., Yao, Q., Hernandez, K. L., Shin, M.-K., Bevans-Fonti, S., Gay, J., Sussan, T. E., Jun, J. C., Myers, A. C., Olivecrona, G., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201209-1688oc · Cited by 175
Cited by
Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets
Ramji, D. P., & Davies, T. S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.04.003 · Cited by 469
The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease
Döring, Y., Pawig, L., Weber, C., & Noels, H. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00212 · Cited by 289
Self-citationCao, Z., Lis, R., Ginsberg, M., Chavez, D., Shido, K., Rabbany, S. Y., Fong, G.-H., Sakmar, T. P., Rafii, S., & Ding, B.-S. (2016) · Nature Medicine · doi:10.1038/nm.4035 · Cited by 285
Inflammatory Chemokines in Atherosclerosis
Gencer, S., Evans, B. R., van der Vorst, E. P. C., Döring, Y., & Weber, C. (2021) · Cells · doi:10.3390/cells10020226 · Cited by 177
Self-citationMIF and CXCL12 in Cardiovascular Diseases: Functional Differences and Similarities
van der Vorst, E. P. C., Döring, Y., & Weber, C. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00373 · Cited by 57
Self-citationEndothelial ACKR3 drives atherosclerosis by promoting immune cell adhesion to vascular endothelium
Gencer, S., Döring, Y., Jansen, Y., Bayasgalan, S., Yan, Y., Bianchini, M., Cimen, I., Müller, M., Peters, L. J. F., Megens, R. T. A., et al. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00937-4 · Cited by 41
Self-citationγ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor
Kim, K., Goldberg, I. J., Graham, M. J., Sundaram, M., Bertaggia, E., Lee, S. X., Qiang, L., Haeusler, R. A., Metzger, D., Chambon, P., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.010 · Cited by 26
Metadata
- Authors
- Li, X., Zhu, M., Penfold, M. E., Koenen, R. R., Thiemann, A., Heyll, K., Akhtar, S., Koyadan, S., Wu, Z., Gremse, F., Kiessling, F., van Zandvoort, M., Schall, T. J., Weber, C., & Schober, A.
- Venue
- Circulation
- Published
- 2014-03-18
- Volume
- 129
- Issue
- 11
- Pages
- 1244-1253
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2082819432
- Cited by
- 64
- References
- 6
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.